{"id":"placebo-to-match-aficamten","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4847050","moleculeType":"Small molecule","molecularWeight":"337.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo matching is used in randomized controlled trials to maintain blinding and reduce bias. This placebo is formulated to be indistinguishable from aficamten (a cardiac myosin inhibitor) in appearance, taste, and administration to ensure trial integrity and allow for valid comparison of aficamten's true therapeutic effects against control.","oneSentence":"This is an inert placebo formulation designed to match the physical and sensory characteristics of aficamten for blinded clinical trial purposes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:42.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Matching placebo for aficamten trials in hypertrophic cardiomyopathy"}]},"trialDetails":[{"nctId":"NCT05186818","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2022-02-01","conditions":"Obstructive Hypertrophic Cardiomyopathy (oHCM)","enrollment":282},{"nctId":"NCT05767346","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2023-06-20","conditions":"Obstructive Hypertrophic Cardiomyopathy (oHCM)","enrollment":175},{"nctId":"NCT05924815","phase":"PHASE1","title":"Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2023-05-15","conditions":"Healthy Participants","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"phase_3","status":"active","brandName":"Placebo to match aficamten","genericName":"Placebo to match aficamten","companyName":"Cytokinetics","companyId":"cytokinetics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is an inert placebo formulation designed to match the physical and sensory characteristics of aficamten for blinded clinical trial purposes. Used for Matching placebo for aficamten trials in hypertrophic cardiomyopathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}